News & Press Releases

ECP in Refractory Glaucoma

December 1, 2017

Journal: Glaucoma Physician | Issue: December 2017 | Author: Juan Carlos Izquierdo, M.D.

How this existing therapy is creating new treatment opportunities for a wider range of patients

We are well aware that the rapidly increasing population of glaucoma patients has generated a surge in the development of new treatments, both pharmaceutical and surgical. This market demand has also incited renewed interest in existing therapies, including endocyclophotocoagulation (ECP).

In ECP, we have an excellent treatment modality, and by slightly modifying the treatment technique, the safety profile improves, so it can be used in a wider variety of patients than previously thought. (con’t)

We use cookies to improve the user experience and for analytics about site information. If you agree to accept our use of cookies, click the "I Agree" button. For further information, please read our privacy policy.

.I Agree